These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 36648946)

  • 1. Association of Sialic Acid-Binding Immunoglobulin-Like Lectin 15 With Phenotypes in Esophageal Squamous Cell Carcinoma in the Setting of Neoadjuvant Chemoradiotherapy.
    Zhou S; Wang Y; Zhang R; Zeng W; Liu S; Liu S; Liu M; Yang H; Xi M
    JAMA Netw Open; 2023 Jan; 6(1):e2250965. PubMed ID: 36648946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy.
    Huang TC; Liang CW; Li YI; Guo JC; Lin CC; Chen YJ; Cheng AL; Hsu CH
    J Cancer Res Clin Oncol; 2022 Jul; 148(7):1803-1811. PubMed ID: 34432128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in Indoleamine 2,3-Dioxygenase 1 Expression and CD8+ Tumor-Infiltrating Lymphocytes after Neoadjuvant Chemoradiation Therapy and Prognostic Significance in Esophageal Squamous Cell Carcinoma.
    Zhou S; Yang H; Zhang J; Wang J; Liang Z; Liu S; Li Y; Pan Y; Zhao L; Xi M
    Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):286-294. PubMed ID: 32004580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression and its clinicopathological correlation in advanced esophageal squamous cell carcinoma in a Chinese population.
    Rong L; Liu Y; Hui Z; Zhao Z; Zhang Y; Wang B; Yuan Y; Li W; Guo L; Ying J; Song Y; Wang L; Zhou Z; Xue L; Lu N
    Diagn Pathol; 2019 Jan; 14(1):6. PubMed ID: 30684971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment biomarkers predicting pathological response to neoadjuvant chemoimmunotherapy in locally advanced esophageal squamous cell carcinoma: post-hoc analysis of a single center, phase 2 study.
    Feng T; Li Q; Zhu R; Yu C; Xu L; Ying L; Wang C; Xu W; Wang J; Zhu J; Huang M; Xu C; Jin J; Zhang X; Lu T; Yang Y; Zhu C; Chen Q; Su D
    J Immunother Cancer; 2024 Aug; 12(8):. PubMed ID: 39209452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed cell death-ligand 1 expression predicts poor treatment response and prognostic value in esophageal squamous cell carcinoma patients without esophagectomy.
    Zhang F; Zhu X; Zhang Q; Zhou P; Hao L
    Aging (Albany NY); 2021 Jul; 13(14):18827-18838. PubMed ID: 34297698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma.
    Guo W; Zhang F; Shao F; Wang P; Li Z; Yang X; He Z; Shi S; Gao Y; He J
    Hum Pathol; 2019 Feb; 84():291-298. PubMed ID: 30296523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec-15 on macrophages suppress the immune microenvironment in patients with PD-L1 negative non-metastasis lung adenocarcinoma.
    Huang Z; Guo Y; Li B; Shen M; Yi Y; Li L; Zhao X; Yang L
    Cancer Gene Ther; 2024 Mar; 31(3):427-438. PubMed ID: 38072971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multi-omics analysis uncovers tumor ecosystem dynamics during neoadjuvant toripalimab plus nab-paclitaxel and S-1 for esophageal squamous cell carcinoma: a single-center, open-label, single-arm phase 2 trial.
    Zhang G; Yuan J; Pan C; Xu Q; Cui X; Zhang J; Liu M; Song Z; Wu L; Wu D; Luo H; Hu Y; Jiao S; Yang B
    EBioMedicine; 2023 Apr; 90():104515. PubMed ID: 36921563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sialic acid-binding immunoglobulin-like lectin-15 expression on peritumoral macrophages is a favorable prognostic factor for primary central nervous system lymphoma patients.
    Fudaba H; Momii Y; Hirakawa T; Onishi K; Asou D; Matsushita W; Kawasaki Y; Sugita K; Fujiki M
    Sci Rep; 2021 Jan; 11(1):1206. PubMed ID: 33441719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China.
    Zhang G; Zhang C; Sun N; Xue L; Yang Z; Fang L; Zhang Z; Luo Y; Gao S; Xue Q; Mu J; Gao Y; Tan F; He J
    J Cancer Res Clin Oncol; 2022 Apr; 148(4):943-954. PubMed ID: 34013382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of a novel immune checkpoint, Siglec-15, in pancreatic ductal adenocarcinoma.
    Chen X; Mo S; Zhang Y; Ma H; Lu Z; Yu S; Chen J
    J Pathol Clin Res; 2022 May; 8(3):268-278. PubMed ID: 35083884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment Esophageal Wall Thickness Associated with Response to Chemoradiotherapy in Locally Advanced Esophageal Cancer.
    Wongwaiyut K; Ruangsin S; Laohawiriyakamol S; Leelakiatpaiboon S; Sangthawan D; Sunpaweravong P; Sunpaweravong S
    J Gastrointest Cancer; 2020 Sep; 51(3):947-951. PubMed ID: 31758468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A tumor immune microenvironment-related integrated signature can predict the pathological response and prognosis of esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A multicenter study in China.
    Wu P; Zhang Z; Yuan Y; Zhang C; Zhang G; Xue L; Yang H; Wang L; Zheng X; Zhang Y; Yuan Y; Lei R; Yang Z; Zheng B; Xue Q; Sun N; He J
    Int J Surg; 2022 Nov; 107():106960. PubMed ID: 36257585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impacts of tumor microenvironment during neoadjuvant chemotherapy in patients with esophageal squamous cell carcinoma.
    Sugawara K; Fukuda T; Murakami C; Oka D; Yoshii T; Amori G; Ishibashi K; Kobayashi Y; Hara H; Kanda H; Motoi N
    Cancer Sci; 2024 Aug; 115(8):2819-2830. PubMed ID: 38693726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic change in Siglec-15 expression in peritumoral macrophages confers an immunosuppressive microenvironment and poor outcome in glioma.
    Chen Q; Chen B; Wang C; Hu L; Wu Q; Zhu Y; Zhang Q
    Front Immunol; 2023; 14():1159085. PubMed ID: 37234161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment absolute lymphocyte count is an independent predictor for survival outcomes for esophageal squamous cell carcinoma patients treated with neoadjuvant chemoradiotherapy and pembrolizumab: An analysis from a prospective cohort.
    Qi WX; Wang X; Li C; Li S; Li H; Xu F; Chen J; Zhao S; Li H
    Thorac Cancer; 2023 Jun; 14(17):1556-1566. PubMed ID: 37089116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in tumour expression of programmed death-ligand 1 after neoadjuvant concurrent chemoradiotherapy in patients with squamous oesophageal cancer.
    Lim SH; Hong M; Ahn S; Choi YL; Kim KM; Oh D; Ahn YC; Jung SH; Ahn MJ; Park K; Zo JI; Shim YM; Sun JM
    Eur J Cancer; 2016 Jan; 52():1-9. PubMed ID: 26623522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.
    Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J
    JAMA Surg; 2021 Aug; 156(8):721-729. PubMed ID: 34160577
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of Radiation-Associated Esophageal Squamous Cell Carcinoma: The MSKCC Experience.
    Nobel TB; Barbetta A; Hsu M; Tan KS; Pinchinat T; Schlottmann F; Bains MS; Ku GY; Wu AJ; Patti MG; Jones DR; Molena D
    J Gastrointest Surg; 2019 Jan; 23(1):11-22. PubMed ID: 30215197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.